Role of abemaciclib in primary breast cancer: a narrative review of MonarchE.

ABSTRACT: Estrogen affects cyclin signaling which results in proliferation of breast cancer cells. Breast cancers expressing hormone receptors (known as hormone receptor-positive or HR+ breast cancers) are characterized by dysregulation of cyclin-dependent kinase 4 and 6 (CDK4/6) activity due to overexpression and amplification of genes associated with the cell cycle. Inhibition of CDK4/6, in combination with endocrine therapy (ET), have shown significant clinical efficacy in treating HR+, human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer, leading to global approval of this combination. Abemaciclib is a CDK4/6 inhibitor with higher potency and inhibits a wider range of CDKs compared with other CDK4/6 inhibitors. The MonarchE study is a global, open-label, randomized ph

SUBMITTER: Takahashi N 

PROVIDER: S-EPMC11092988 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature